Plans for anemia drug run into roadblocks
Hospital, firm eyed $12b market
A licensing deal between Beth Israel Deaconess Medical Center and a Florida biotechnology company to produce a "super" form of an anti anemia drug is in danger of foundering just two years after it was signed. (Full article: 1036 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
